Covered recipient · General Payments record
LAWRENCE D SHER
Allopathic & Osteopathic Physicians Pediatrics
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$37,213.58
111 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,002.70 | 17 |
| Travel and Lodging | $3,741.16 | 6 |
| Food and Beverage | $2,469.72 | 88 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $17,272.70 | 39 |
| Regeneron Healthcare Solutions, Inc. | $12,032.26 | 19 |
| GlaxoSmithKline, LLC. | $4,032.21 | 10 |
| GENZYME CORPORATION | $1,807.51 | 7 |
| PFIZER INC. | $1,531.26 | 11 |
| AstraZeneca Pharmaceuticals LP | $161.09 | 6 |
| Amgen Inc. | $58.21 | 3 |
| Corium, LLC | $48.26 | 3 |
| Genentech USA, Inc. | $45.16 | 2 |
| Merck Sharp & Dohme LLC | $44.44 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $37.46 | 2 |
| Regeneron Pharmaceuticals, Inc. | $29.60 | 1 |
| Incyte Corporation | $28.62 | 1 |
| kaleo, Inc. | $23.02 | 1 |
| Lilly USA, LLC | $19.16 | 1 |
| Cranial Technologies, Inc | $15.00 | 1 |
| Kowa Pharmaceuticals America, Inc. | $14.19 | 1 |
| Phadia US Inc. | $13.43 | 1 |
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LAWRENCE D SHER
NPI 1912923913 · CMS profile ID 86506
Allopathic & Osteopathic Physicians / Pediatrics
ROLLING HILLS ESTATES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LAWRENCE D SHER, NPI 1912923913, CMS profile ID 86506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). LAWRENCE D SHER, NPI 1912923913, CMS profile ID 86506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- LAWRENCE D SHER, NPI 1912923913, CMS profile ID 86506, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1912923913?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
111 matching records · $37,213.58 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–111 of 111.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $21.82 | 02/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998967879 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1.53 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999438443 | CMS |
| Regeneron Healthcare Solutions, Inc. | $0.84 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999438449 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2.32 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999438455 | CMS |
| AbbVie Inc. | $22.13 | 01/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998967871 | CMS |
| AbbVie Inc. | $2.52 | 01/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998967875 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.85 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015167605 | CMS |
| Regeneron Healthcare Solutions, Inc. | $30.95 | 01/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999438437 | CMS |
| AbbVie Inc. | $28.05 | 01/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998967867 | CMS |
| AbbVie Inc. | $5.83 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998967863 | CMS |
| Kowa Pharmaceuticals America, Inc. | $14.19 | 01/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003845847 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $6,061,303.99 | 321 |
| PY2024 | Recipient | $29,331.55 | 17 |
| PY2024 | Principal investigator | $7,111,011.48 | 216 |
| PY2023 | Recipient | $14,443.64 | 20 |
| PY2023 | Principal investigator | $7,232,124.60 | 4,231 |
| PY2022 | Recipient | $108,639.12 | 16 |
| PY2022 | Principal investigator | $7,703,527.25 | 144 |
| PY2021 | Recipient | $133,070.70 | 39 |
| PY2021 | Principal investigator | $6,913,610.43 | 156 |
| PY2020 | Recipient | $519,510.56 | 81 |
| PY2020 | Principal investigator | $1,777,135.06 | 125 |
| PY2019 | Recipient | $329,908.59 | 150 |
| PY2019 | Principal investigator | $1,346,770.32 | 191 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
321 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,594.40 | 12/19/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192120958 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 12/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989988 |
| Principal investigator 1 | ModernaTX, Inc. | $33.75 | 12/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990018 |
| Principal investigator 1 | ModernaTX, Inc. | $11,609.95 | 12/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001635 |
| Principal investigator 1 | ModernaTX, Inc. | $5,475.80 | 12/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001697 |
| Principal investigator 1 | PFIZER INC. | $2,348.50 | 12/17/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228732758 |
| Principal investigator 1 | ModernaTX, Inc. | $303.75 | 12/15/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989946 |
| Principal investigator 1 | ModernaTX, Inc. | $263.25 | 12/15/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990032 |
| Principal investigator 1 | Amgen Inc. | $4,546.92 | 12/12/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2) | No dispute reported | 06/30/2026 | 1246646420 |
| Principal investigator 1 | Amgen Inc. | $19,993.92 | 12/12/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity | No dispute reported | 06/30/2026 | 1246646424 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,132.00 | 12/05/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.06 | 12/04/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184269461 |
| Principal investigator 1 | ModernaTX, Inc. | $445.50 | 12/03/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989984 |
| Principal investigator 1 | ModernaTX, Inc. | $101.25 | 12/03/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990010 |
| Principal investigator 1 | PFIZER INC. | $587.50 | 12/02/2025 | Non-covered Recipient Entity Peninsula Research Associates | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228718658 |
| Principal investigator 1 | ModernaTX, Inc. | $4,779.02 | 12/01/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989936 |
| Principal investigator 1 | ModernaTX, Inc. | $27,043.92 | 12/01/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989940 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $203.00 | 12/01/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347891 |
| Principal investigator 1 | ModernaTX, Inc. | $322.05 | 11/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001633 |
| Principal investigator 1 | ModernaTX, Inc. | $5,977.40 | 11/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001687 |
| Principal investigator 1 | ModernaTX, Inc. | $41,162.55 | 11/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001709 |
| Principal investigator 1 | PFIZER INC. | $20,850.00 | 11/27/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228724562 |
| Principal investigator 1 | PFIZER INC. | $5,721.40 | 11/26/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228738516 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $223.00 | 11/25/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226116029 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $16,834.50 | 11/17/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226116019 |
| Principal investigator 1 | PFIZER INC. | $221.58 | 11/13/2025 | Non-covered Recipient Entity Peninsula Research Associates | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228720053 |
| Principal investigator 1 | PFIZER INC. | $272.70 | 11/13/2025 | Non-covered Recipient Entity Peninsula Research Associates | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228728251 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 11/12/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192120932 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 11/12/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192120945 |
| Principal investigator 1 | ModernaTX, Inc. | $820.12 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989948 |
| Principal investigator 1 | ModernaTX, Inc. | $2,056.56 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989954 |
| Principal investigator 1 | ModernaTX, Inc. | $13,104.30 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989958 |
| Principal investigator 1 | ModernaTX, Inc. | $7,267.54 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989960 |
| Principal investigator 1 | ModernaTX, Inc. | $1,997.52 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989996 |
| Principal investigator 1 | ModernaTX, Inc. | $2,416.95 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989998 |
| Principal investigator 1 | ModernaTX, Inc. | $7,541.71 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990000 |
| Principal investigator 1 | ModernaTX, Inc. | $5,723.02 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990022 |
| Principal investigator 1 | ModernaTX, Inc. | $138.10 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990026 |
| Principal investigator 1 | ModernaTX, Inc. | $14,057.20 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990030 |
| Principal investigator 1 | ModernaTX, Inc. | $14,442.50 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990036 |
| Principal investigator 1 | ModernaTX, Inc. | $4,900.80 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990050 |
| Principal investigator 1 | ModernaTX, Inc. | $14,337.75 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990058 |
| Principal investigator 1 | ModernaTX, Inc. | $6,173.30 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990060 |
| Principal investigator 1 | ModernaTX, Inc. | $5,955.95 | 11/10/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990062 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,805.00 | 11/05/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192120971 |
| Principal investigator 1 | PFIZER INC. | $6,260.10 | 11/05/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228728794 |
| Principal investigator 1 | Eli Lilly and Company | $16,000.40 | 11/04/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 52-WEEK STUDY, TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH UNCONTROLLED MODERATE TO SEVERE ASTHMA | No dispute reported | 06/30/2026 | 1187888676 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $203.00 | 11/01/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347877 |
| Principal investigator 1 | ModernaTX, Inc. | $1,750.00 | 10/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990024 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990028 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 10/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990052 |
| Principal investigator 1 | ModernaTX, Inc. | $894.00 | 10/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990054 |
| Principal investigator 1 | PFIZER INC. | $2,348.50 | 10/29/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228759371 |
| Principal investigator 1 | ModernaTX, Inc. | $4,186.65 | 10/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001647 |
| Principal investigator 1 | ModernaTX, Inc. | $6,165.50 | 10/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001675 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/24/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989944 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 10/24/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990002 |
| Principal investigator 1 | ModernaTX, Inc. | $67.50 | 10/24/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $906.88 | 10/23/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252800 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $23,753.25 | 10/23/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226116025 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $308,890.30 | 10/22/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA | No dispute reported | 06/30/2026 | 1185552823 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/22/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989994 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $66,865.50 | 10/10/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226116014 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,882.00 | 10/10/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,457.41 | 10/03/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184244815 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $203.00 | 10/01/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347783 |
| Principal investigator 1 | ModernaTX, Inc. | $5,872.90 | 09/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001663 |
| Principal investigator 1 | ModernaTX, Inc. | $4,508.70 | 09/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001701 |
| Principal investigator 1 | PFIZER INC. | $3,911.60 | 09/26/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228751835 |
| Principal investigator 1 | Incyte Corporation | $1,575.00 | 09/23/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES PRA | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576483 |
| Principal investigator 1 | Incyte Corporation | $2,174.00 | 09/23/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES PRA | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576489 |
| Principal investigator 1 | Incyte Corporation | $18,000.00 | 09/23/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES PRA | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576500 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 09/12/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES PRA | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240576495 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $203.00 | 09/01/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347747 |
| Principal investigator 1 | ModernaTX, Inc. | $1,055.45 | 08/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001661 |
| Principal investigator 1 | ModernaTX, Inc. | $6,228.20 | 08/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001685 |
| Principal investigator 1 | ModernaTX, Inc. | $14,814.30 | 08/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001711 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $9,250.00 | 08/27/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347412 |
| Principal investigator 1 | PFIZER INC. | $18,935.50 | 08/23/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228767082 |
| Principal investigator 1 | ModernaTX, Inc. | $51,991.92 | 08/22/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989986 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $20.00 | 08/20/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192120965 |
| Principal investigator 1 | Eli Lilly and Company | $133,221.07 | 08/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LY3549492 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS 55 TO 80 YEARS OF AGE AND BMI WITHIN 22 TO 25 KG/M2 | No dispute reported | 06/30/2026 | 1187887606 |
| Principal investigator 1 | ModernaTX, Inc. | $325.00 | 08/06/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012294 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $203.00 | 08/01/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347871 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $149.10 | 07/30/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347827 |
| Principal investigator 1 | PFIZER INC. | $13,503.00 | 07/29/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228772701 |
| Principal investigator 1 | ModernaTX, Inc. | $1,588.40 | 07/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001683 |
| Principal investigator 1 | ModernaTX, Inc. | $5,277.25 | 07/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001713 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $1,050.00 | 07/24/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347949 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $820.05 | 07/22/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347739 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $260.40 | 07/22/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347867 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $60.90 | 07/18/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347713 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $0.11 | 07/18/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347811 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.08 | 07/17/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,122.71 | 07/17/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.08 | 07/17/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217252 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $390.12 | 07/17/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217254 |
| Principal investigator 1 | ModernaTX, Inc. | $60,453.00 | 07/09/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989992 |
| Principal investigator 1 | ModernaTX, Inc. | $264.00 | 07/09/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002589 |
| Principal investigator 1 | PFIZER INC. | $18,774.70 | 07/02/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228773483 |
| Principal investigator 1 | ROCHE MOLECULAR SYSTEMS, INC. | $203.00 | 07/01/2025 | Non-covered Recipient Entity PENINSULA RESEARCH ASSOCIATES | RD006866 | No dispute reported | 06/30/2026 | 1244347719 |
| Principal investigator 1 | ModernaTX, Inc. | $322.05 | 06/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001649 |
| Principal investigator 1 | ModernaTX, Inc. | $12,665.40 | 06/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001659 |
| Principal investigator 1 | ModernaTX, Inc. | $5,099.60 | 06/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001707 |
| Principal investigator 1 | ModernaTX, Inc. | $7,224.75 | 06/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002583 |
| Principal investigator 1 | ModernaTX, Inc. | $94,824.40 | 06/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012302 |
| Principal investigator 1 | ModernaTX, Inc. | $23,672.48 | 06/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012322 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,750.00 | 06/26/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185552825 |
| Principal investigator 1 | ModernaTX, Inc. | $325.00 | 06/26/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012306 |
| Principal investigator 1 | ModernaTX, Inc. | $264.00 | 06/26/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012332 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,224.20 | 06/20/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150354 |
| Principal investigator 1 | ModernaTX, Inc. | $8,695.35 | 06/18/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001693 |
| Principal investigator 1 | ModernaTX, Inc. | $17,942.65 | 06/18/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001705 |
| Principal investigator 1 | ModernaTX, Inc. | $5,768.40 | 06/18/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001715 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $377,512.52 | 06/17/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115978 |
| Principal investigator 1 | ModernaTX, Inc. | $2,516.00 | 06/06/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989980 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 06/06/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989982 |
| Principal investigator 1 | ModernaTX, Inc. | $2,644.00 | 06/06/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989990 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/06/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990014 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/06/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990046 |
| Principal investigator 1 | ModernaTX, Inc. | $33.75 | 06/06/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990048 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 06/04/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989952 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/04/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990016 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $96,880.05 | 06/02/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115971 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,842.00 | 06/02/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150347 |
| Principal investigator 1 | ModernaTX, Inc. | $675.00 | 05/30/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012316 |
| Principal investigator 1 | PFIZER INC. | $17,025.40 | 05/30/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228773636 |
| Principal investigator 1 | ModernaTX, Inc. | $125.00 | 05/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989956 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 05/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990056 |
| Principal investigator 1 | ModernaTX, Inc. | $44,328.90 | 05/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001639 |
| Principal investigator 1 | ModernaTX, Inc. | $9,983.55 | 05/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001667 |
| Principal investigator 1 | ModernaTX, Inc. | $6,416.30 | 05/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001703 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $392.00 | 05/22/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150637 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $392.00 | 05/22/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150645 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $98.00 | 05/22/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150653 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,615.00 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115910 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $21,784.00 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115916 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,758.40 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115922 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $439.60 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115926 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,318.80 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115931 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $879.20 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115935 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $879.20 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115940 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $879.20 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115945 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115951 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,724.00 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150628 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $882.00 | 05/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150634 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,000.00 | 05/20/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115872 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,046.40 | 05/20/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115886 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,940.00 | 05/20/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115892 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,883.60 | 05/20/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115898 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $279.45 | 05/20/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115904 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $606.06 | 05/20/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226116008 |
| Principal investigator 1 | PFIZER INC. | $23,728.15 | 05/14/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228766841 |
| Principal investigator 1 | PFIZER INC. | $907.20 | 05/10/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1228776156 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,192.00 | 05/09/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150622 |
| Principal investigator 1 | Eli Lilly and Company | $895.23 | 05/08/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187888130 |
| Principal investigator 1 | ModernaTX, Inc. | $33.75 | 05/07/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989938 |
| Principal investigator 1 | ModernaTX, Inc. | $33.75 | 05/07/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989978 |
| Principal investigator 1 | ModernaTX, Inc. | $33.75 | 05/07/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990008 |
| Principal investigator 1 | PFIZER INC. | $488.60 | 05/06/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228781742 |
| Principal investigator 1 | Eli Lilly and Company | $4,375.00 | 05/05/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187885628 |
| Principal investigator 1 | PFIZER INC. | $8,098.30 | 05/03/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228773646 |
| Principal investigator 1 | ModernaTX, Inc. | $250.00 | 05/02/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012312 |
| Principal investigator 1 | ModernaTX, Inc. | $450.00 | 05/02/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012328 |
| Principal investigator 1 | Eli Lilly and Company | $139.18 | 04/30/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187888940 |
| Principal investigator 1 | PFIZER INC. | $495.60 | 04/29/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1228778880 |
| Principal investigator 1 | ModernaTX, Inc. | $5,956.50 | 04/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001655 |
| Principal investigator 1 | ModernaTX, Inc. | $26,408.10 | 04/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001677 |
| Principal investigator 1 | ModernaTX, Inc. | $87,694.88 | 04/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002585 |
| Principal investigator 1 | ModernaTX, Inc. | $54,908.10 | 04/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012324 |
| Principal investigator 1 | ModernaTX, Inc. | $91,807.26 | 04/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012326 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,082.40 | 04/28/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115964 |
| Principal investigator 1 | ModernaTX, Inc. | $58,441.51 | 04/23/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989942 |
| Principal investigator 1 | ModernaTX, Inc. | $1,750.00 | 04/23/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989974 |
| Principal investigator 1 | ModernaTX, Inc. | $1,750.00 | 04/23/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990012 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 04/23/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252990044 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,583.70 | 04/16/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226116005 |
| Principal investigator 1 | PFIZER INC. | $5,600.00 | 04/15/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1228791558 |
| Principal investigator 1 | ModernaTX, Inc. | $22,499.10 | 04/09/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012300 |
| Principal investigator 1 | PFIZER INC. | $10,709.40 | 04/09/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228778753 |
| Principal investigator 1 | Eli Lilly and Company | $2,722.60 | 04/08/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187885626 |
| Principal investigator 1 | Eli Lilly and Company | $924.70 | 04/08/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187888674 |
| Principal investigator 1 | Eli Lilly and Company | $2,710.65 | 04/08/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890124 |
| Principal investigator 1 | Eli Lilly and Company | $2,524.12 | 04/08/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187890440 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $810.00 | 04/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115988 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $152.55 | 04/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115995 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,000.00 | 04/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115999 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 04/01/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012330 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $527.85 | 04/01/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115983 |
| Principal investigator 1 | PFIZER INC. | $10,249.80 | 03/29/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | No dispute reported | 06/30/2026 | 1228788019 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,135.60 | 03/28/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150401 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,750.00 | 03/27/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115852 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $191.70 | 03/27/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115858 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $184,796.10 | 03/26/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115845 |
| Principal investigator 1 | ModernaTX, Inc. | $325.00 | 03/25/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002587 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $121,400.30 | 03/25/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150379 |
| Principal investigator 1 | ModernaTX, Inc. | $686.85 | 03/24/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001643 |
| Principal investigator 1 | ModernaTX, Inc. | $6,144.60 | 03/24/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001651 |
| Principal investigator 1 | ModernaTX, Inc. | $20,611.20 | 03/24/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001671 |
| Principal investigator 1 | ModernaTX, Inc. | $4,221.80 | 03/24/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001699 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $51,585.80 | 03/21/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150374 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $65.02 | 03/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,652.47 | 03/11/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184170766 |
| Principal investigator 1 | PFIZER INC. | $9,293.10 | 03/04/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228780209 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $78,678.60 | 03/04/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150368 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 03/03/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192114647 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 03/03/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192120939 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 03/03/2025 | Non-covered Recipient Entity HEADLANDS HORIZONS LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192120951 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,670.20 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115775 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $22,612.80 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115783 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,826.60 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115790 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115793 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,500.00 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115800 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $960.00 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115806 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $250.00 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115811 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $879.20 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115814 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115820 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,670.20 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115827 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $950.00 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226115834 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $477,269.55 | 03/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115839 |
| Principal investigator 1 | ModernaTX, Inc. | $15,249.00 | 02/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012304 |
| Principal investigator 1 | ModernaTX, Inc. | $264.00 | 02/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012314 |
| Principal investigator 1 | ModernaTX, Inc. | $557.70 | 02/28/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012318 |
| Principal investigator 1 | ModernaTX, Inc. | $1,581.32 | 02/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252989950 |
| Principal investigator 1 | ModernaTX, Inc. | $20,933.25 | 02/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001637 |
| Principal investigator 1 | ModernaTX, Inc. | $1,630.20 | 02/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001645 |
| Principal investigator 1 | ModernaTX, Inc. | $21,109.00 | 02/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001657 |
| Principal investigator 1 | ModernaTX, Inc. | $6,646.20 | 02/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001665 |
| Principal investigator 1 | ModernaTX, Inc. | $16,777.00 | 02/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001669 |
| Principal investigator 1 | ModernaTX, Inc. | $625.00 | 02/26/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989964 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 02/26/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989970 |
| Principal investigator 1 | ModernaTX, Inc. | $1,746.00 | 02/26/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990042 |
| Principal investigator 1 | Eli Lilly and Company | $79,513.00 | 02/25/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187888672 |
| Principal investigator 1 | ModernaTX, Inc. | $22,034.38 | 02/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989932 |
| Principal investigator 1 | ModernaTX, Inc. | $1,400.00 | 02/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989934 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 02/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989966 |
| Principal investigator 1 | ModernaTX, Inc. | $23,603.28 | 02/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989972 |
| Principal investigator 1 | ModernaTX, Inc. | $1,626.00 | 02/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990004 |
| Principal investigator 1 | ModernaTX, Inc. | $2,153.25 | 02/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990006 |
| Principal investigator 1 | ModernaTX, Inc. | $1,329.75 | 02/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990040 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 02/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989968 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 02/19/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990038 |
| Principal investigator 1 | ModernaTX, Inc. | $3,355.40 | 02/17/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001673 |
| Principal investigator 1 | Eli Lilly and Company | $487,121.01 | 02/11/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187888670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,984.80 | 02/11/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184153052 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $257,314.47 | 02/11/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115879 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150574 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150580 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150589 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150597 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150604 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,058.00 | 02/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150610 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,204.80 | 02/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150616 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $825.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150390 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $686.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150394 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $495.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150406 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $392.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150413 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $495.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150419 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $630.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150424 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $350.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150429 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $420.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150434 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $224.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150442 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $106.40 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150447 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $231.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150454 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $98.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150461 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,254.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150467 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $98.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150475 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150486 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150491 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $686.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150498 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150503 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150509 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $392.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150517 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,666.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150523 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150529 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $686.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150537 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $490.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150547 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $588.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150552 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $196.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150557 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,450.00 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150561 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $59,322.20 | 02/06/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150569 |
| Principal investigator 1 | ModernaTX, Inc. | $11,069.24 | 02/05/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252990034 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $53.30 | 02/05/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184152516 |
| Principal investigator 1 | Eli Lilly and Company | $90.00 | 01/31/2025 | Non-covered Recipient Entity PALOS VERDES MEDICAL GROUP | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187885262 |
| Principal investigator 1 | Eli Lilly and Company | $4,048.73 | 01/31/2025 | Non-covered Recipient Entity PALOS VERDES MEDICAL GROUP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187888318 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $90,400.80 | 01/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Phase I Openlabel Randomized ActiveControlled Study in Adults to Characterize the Safety and Immunogenicity of AZD9838 Vaccine ARTEMIS C | No dispute reported | 06/30/2026 | 1185552821 |
| Principal investigator 1 | ModernaTX, Inc. | $767.57 | 01/29/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252989962 |
| Principal investigator 1 | ModernaTX, Inc. | $6,332.70 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001631 |
| Principal investigator 1 | ModernaTX, Inc. | $36,909.40 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001641 |
| Principal investigator 1 | ModernaTX, Inc. | $3,636.60 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001679 |
| Principal investigator 1 | ModernaTX, Inc. | $3,302.20 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001689 |
| Principal investigator 1 | ModernaTX, Inc. | $17,068.65 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001695 |
| Principal investigator 1 | ModernaTX, Inc. | $27,454.05 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012298 |
| Principal investigator 1 | ModernaTX, Inc. | $5,075.85 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012308 |
| Principal investigator 1 | ModernaTX, Inc. | $19,720.48 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012310 |
| Principal investigator 1 | ModernaTX, Inc. | $40,084.86 | 01/27/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012320 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,486.35 | 01/27/2025 | Non-covered Recipient Entity Peninsula Research Associates | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1226116376 |
| Principal investigator 1 | ModernaTX, Inc. | $10,800.00 | 01/22/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001653 |
| Principal investigator 1 | Eli Lilly and Company | $87,573.00 | 01/21/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187885624 |
| Principal investigator 1 | Eli Lilly and Company | $1,668.18 | 01/21/2025 | Non-covered Recipient Entity PALOS VERDES MEDICAL GROUP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187889764 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 01/20/2025 | Non-covered Recipient Entity Peninsula Research Associates,inc | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113997 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 01/20/2025 | Non-covered Recipient Entity Peninsula Research Associates,inc | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1226114002 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 01/20/2025 | Non-covered Recipient Entity Peninsula Research Associates | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1226116372 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $95,423.75 | 01/16/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A randomized, modified double-blind, active controlled study to characterize the immunogenicity and safety of IVX-A12 | No dispute reported | 06/30/2026 | 1185552819 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 01/16/2025 | Non-covered Recipient Entity Peninsula Research Associates,inc | A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113991 |
| Principal investigator 1 | PFIZER INC. | $8,118.60 | 01/15/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228798472 |
| Principal investigator 1 | PFIZER INC. | $3,585.00 | 01/15/2025 | Non-covered Recipient Entity Peninsula Headlands LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228799309 |
| Principal investigator 1 | ModernaTX, Inc. | $199.56 | 01/13/2025 | Non-covered Recipient Entity Peninsula Research Associates | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001691 |
| Principal investigator 1 | Eli Lilly and Company | $6,510.55 | 01/09/2025 | Non-covered Recipient Entity PALOS VERDES MEDICAL GROUP | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187885264 |
| Principal investigator 1 | Eli Lilly and Company | $3,084.09 | 01/09/2025 | Non-covered Recipient Entity PALOS VERDES MEDICAL GROUP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187885266 |
| Principal investigator 1 | Eli Lilly and Company | $9,079.66 | 01/09/2025 | Non-covered Recipient Entity PALOS VERDES MEDICAL GROUP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187887494 |
| Principal investigator 1 | Eli Lilly and Company | $688.27 | 01/09/2025 | Non-covered Recipient Entity PALOS VERDES MEDICAL GROUP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187888932 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 01/08/2025 | Non-covered Recipient Entity Peninsula Research Associates | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001681 |
| Principal investigator 1 | Eli Lilly and Company | $200,272.00 | 01/07/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187887604 |
| Principal investigator 1 | Eli Lilly and Company | $83,642.00 | 01/07/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187888938 |
| Principal investigator 1 | Eli Lilly and Company | $327,825.00 | 01/07/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187888942 |
| Principal investigator 1 | Eli Lilly and Company | $217,429.00 | 01/07/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187890122 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $173,889.06 | 01/07/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226115864 |
| Principal investigator 1 | ModernaTX, Inc. | $3,408.78 | 01/03/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252989976 |
| Principal investigator 1 | ModernaTX, Inc. | $8,800.00 | 01/03/2025 | Non-covered Recipient Entity PENINSULA HEADLANDS LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012296 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,184.40 | 01/03/2025 | Non-covered Recipient Entity Peninsula Headlands Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226150385 |